IL234033A0 - Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for the treatment of overactive bladder - Google Patents

Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for the treatment of overactive bladder

Info

Publication number
IL234033A0
IL234033A0 IL234033A IL23403314A IL234033A0 IL 234033 A0 IL234033 A0 IL 234033A0 IL 234033 A IL234033 A IL 234033A IL 23403314 A IL23403314 A IL 23403314A IL 234033 A0 IL234033 A0 IL 234033A0
Authority
IL
Israel
Prior art keywords
beta
combination
receptor antagonists
muscarinic receptor
overactive bladder
Prior art date
Application number
IL234033A
Other languages
English (en)
Hebrew (he)
Original Assignee
Stephen Caltabiano
Eliot Ohlstein
Stewart Mccallum
Altherx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stephen Caltabiano, Eliot Ohlstein, Stewart Mccallum, Altherx Inc filed Critical Stephen Caltabiano
Publication of IL234033A0 publication Critical patent/IL234033A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL234033A 2012-02-09 2014-08-10 Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for the treatment of overactive bladder IL234033A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596893P 2012-02-09 2012-02-09
PCT/US2013/025285 WO2013119910A1 (en) 2012-02-09 2013-02-08 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder

Publications (1)

Publication Number Publication Date
IL234033A0 true IL234033A0 (en) 2014-09-30

Family

ID=48948043

Family Applications (1)

Application Number Title Priority Date Filing Date
IL234033A IL234033A0 (en) 2012-02-09 2014-08-10 Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for the treatment of overactive bladder

Country Status (13)

Country Link
EP (1) EP2811989A1 (ko)
JP (1) JP2015509931A (ko)
KR (1) KR20150020160A (ko)
CN (1) CN104684549A (ko)
AR (1) AR089957A1 (ko)
AU (1) AU2013216864A1 (ko)
CA (1) CA2864173A1 (ko)
HK (1) HK1204966A1 (ko)
IL (1) IL234033A0 (ko)
PH (1) PH12014501814A1 (ko)
SG (1) SG11201404776PA (ko)
TW (1) TW201338772A (ko)
WO (1) WO2013119910A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (ko) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20100113469A1 (en) * 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2470021B1 (en) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
CA2774992A1 (en) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Also Published As

Publication number Publication date
WO2013119910A1 (en) 2013-08-15
TW201338772A (zh) 2013-10-01
AU2013216864A1 (en) 2014-09-11
PH12014501814A1 (en) 2014-11-24
SG11201404776PA (en) 2014-09-26
KR20150020160A (ko) 2015-02-25
CN104684549A (zh) 2015-06-03
JP2015509931A (ja) 2015-04-02
EP2811989A1 (en) 2014-12-17
CA2864173A1 (en) 2013-08-15
AR089957A1 (es) 2014-10-01
HK1204966A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
HRP20180915T1 (hr) Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
SG10201506076TA (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
EP2841154A4 (en) BLADDER TISSUE MODIFICATION FOR HYPERACTIVE BLADDER TROUBLESHOOTING
HRP20151103T1 (en) Substituted triazolopyridines and their use as ttk inhibitors
EP2680853A4 (en) TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
PL2928890T3 (pl) Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
AP2014008011A0 (en) Agents for treating disorders involving modulationof ryanodine receptors
EP2709991A4 (en) USE OF CXCR4 ANTAGONISTS
IL238665B (en) Compositions for the permanent hydrophilization of fibers made from polyolefin and use of these compositions
HK1204966A1 (en) Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder -3
PL2682103T3 (pl) Kompozycje zawierające antagonistę receptora muskarynowego i sorbitol
IL237150B (en) Preparations containing combinations of receptor antagonists and agonists
HK1202459A1 (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
EP2862577A4 (en) USE OF OBESTATIN FOR MUSCLE REGENERATION
IL238120B (en) Combination of adrenalin with an antidepressant for use in the treatment of shock
PT2709991T (pt) Uso de antagonistas de cxcr4 para tratar síndrome de whim, mielocatexia, neutropenia e linfocitopenia
PL395618A1 (pl) Urzadzenie do stabilizacyjnego wzmacniania wlókien miesni